{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:16:03Z","timestamp":1740158163556,"version":"3.37.3"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clml.2020.11.005","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T02:53:13Z","timestamp":1605063193000},"page":"246-256.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4783-2643","authenticated-orcid":false,"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-2737","authenticated-orcid":false,"given":"Bradley","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Varnavski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Pampaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-5321","authenticated-orcid":false,"given":"Lloyd","family":"Damon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-6227","authenticated-orcid":false,"given":"Charalambos B.","family":"Andreadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.11.005_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.11.005_bib2","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.11.005_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1083-8791(01)80003-3","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin\u2019s lymphoma: an evidence-based review","volume":"7","author":"Hahn","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.11.005_bib6","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.1994.12.12.2559","article-title":"High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma","volume":"12","author":"Weaver","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib7","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.1998.16.10.3264","article-title":"Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial","volume":"16","author":"Guglielmi","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib8","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib9","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib11","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","article-title":"Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas","volume":"16","author":"Sarkozy","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"Perry","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.005_bib13","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"Grup per l\u2019Estudi dels Limfomes de Catalunya i Balears (GELCAB). MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.11.005_bib14","doi-asserted-by":"crossref","first-page":"e95020","DOI":"10.1371\/journal.pone.0095020","article-title":"C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.11.005_bib15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.005_bib16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.005_bib17","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3109\/10428194.2014.975803","article-title":"Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma","volume":"56","author":"Farooq","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.11.005_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/bmt.2008.236","article-title":"Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin\u2019s lymphoma","volume":"42","author":"Damon","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.11.005_bib19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.11.005_bib20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib21","doi-asserted-by":"crossref","first-page":"2694a","DOI":"10.1182\/blood.V110.11.2346.2346","article-title":"Chemotherapy-refractory diffuse large B-cell lymphomas are effectively killed by ofatumumab-induced complement-mediated cytotoxicity","volume":"110","author":"Cilessen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3955.3955","article-title":"Ofatumumab monotherapy for treatment of patients with relapsed\/progressive diffuse large B-cell lymphoma: results of a mutlicenter phase II study","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD Study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.1997.15.2.833","article-title":"High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency","volume":"15","author":"Smith","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14737159.2019.1627877","article-title":"ClonoSEQ assay for the detection of lymphoid malignancies","volume":"19","author":"Monter","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.clml.2020.11.005_bib26","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/ncomms3680","article-title":"Using synthetic templates to design an unbiased multiplex PCR assay","volume":"4","author":"Carlson","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2020.11.005_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.11.005_bib29","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a Bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib30","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.11.005_bib31","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib33","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2020.11.005_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.12439","article-title":"Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma","volume":"163","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.005_bib35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fonc.2019.00528","article-title":"The minimal residual disease in non-Hodgkin\u2019s lymphomas: from the laboratory to the clinical practice","volume":"9","author":"Galimberti","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2020.11.005_bib36","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib37","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.11.005_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.11.005_bib40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2017.167627","article-title":"Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?","volume":"102","author":"Ferrero","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.11.005_bib41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2020.11.005_bib42","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib43","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.005_bib44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.005_bib45","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:35:58Z","timestamp":1730529358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020306297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2152265020306297"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}